Company overview
CENTOGENE provides advanced genetic and multiomic testing for rare, neurodegenerative, neurological, oncology, endocrinology, and other diseases, powered by the world's largest genetic testing portfolio covering 19,000 genes and the CENTOGENE Biodatabank. Their solutions include genome-wide CNV analysis via CentoArray, comprehensive NGS panels like CentoNeuro, and global sample logistics with CentoCard. The company aims to cure 100 rare diseases in the next decade, prioritizing neurological and metabolic disorders.
CENTOGENE Guiding Precision Medicine is listed in the NovaPharmaNews Supplier Hub as a Diagnostics & Testing partner serving United States & Americas. Core focus areas include genetic testing, rare diseases, ngs panels, multiomic diagnostics, precision medicine.
Industry categories: Diagnostics & Testing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Products and technologies associated with CENTOGENE Guiding Precision Medicine include Diagnostic — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://www.centogene.com
- Categories
- Diagnostics & Testing
- Markets served
- United States & Americas
- Keywords
- genetic testing, rare diseases, ngs panels, multiomic diagnostics, precision medicine
Products & technologies
Therapeutic areas
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What diagnostic capabilities does CENTOGENE offer?
- CENTOGENE offers the world's largest genetic testing portfolio with 19,000 genes, including NGS panels for neurology (CentoNeuro), oncology, endocrinology, osteology, ENT, and genome-wide CNV analysis via CentoArray, powered by their Biodatabank and global network.
- What is CENTOGENE's focus in rare disease research?
- CENTOGENE has a mission to cure 100 rare diseases within the next 10 years, prioritizing rare neurological and metabolic disorders like Gaucher and Parkinson’s, with goals to expand their biobank to one million patients and develop 10 full disease models.
- What geographies and logistics does CENTOGENE support?
- CENTOGENE operates a global clinical network and proprietary CentoCard-based sample logistics system for rapid worldwide diagnostics, serving patients from neonatal cases to adults with complex disorders.
Related editorial coverage
- FDA CBER Patient Listening Meeting on Gene Therapy Safety: Patient and Care Partner Perspectives
- Gene Therapy FDA Approval for Rare Disease: Updated List and Analysis
- Immunovant's IMVT-1402 Shows Blockbuster Potential in Autoimmune Disease; Wave Life Sciences Advances RNA Editing
- Palvella Secures $230M to Advance QTORIN for Rare Diseases
- Palvella's Pivotal Rare-Disease Data and Financial Outlook
- Bio-IT World Conference: Oncology Highlights - Day 1
Explore lab tools and QA/QC resources for R&D teams.
